Background: Breast cancer is a type of cancer due to abnormal cell growth of breast tissue. CD44 and CD24 is a potential target in breast cancer therapy. This study aims to evaluate the responsiveness of stage 3 breast cancer to chemotherapy by measuring the expression levels of CD44 and CD24 molecules
Methods: We conducted an observational study with pre-and â€“post-intervention or test research types. This study was performed on 49 Luminal Stadium IIIB subtype breast cancer patients who received 3 series of neoadjuvant chemotherapy at RSUD dr. Saiful Anwar Malang, immunohistochemical examination, and painting of tissue specimens from the biopsy results. Data were analyzed using SPSS version 20 for Windows.
Results: Based on the Paired t-test and discriminant analysis, there were no significant differences between CD44 and CD24 expression before and after chemotherapy (p=0.501 and p=0.097, respectively). Therefore, the results of the study prompt that the expression of CD44 and CD24 could not be a predictor of the chemotherapy response.
Conclusion: There are different expressions of CD44 and CD44 in primary breast cancer before and after chemotherapy, but no significant difference was found.